Simulations Plus (NASDAQ:SLP) offers advanced modeling software for the pharmaceutical and biotechnology industries within nasdaq today.

Simulations Plus reported a 9% increase in total revenue in Q3 2023, driven by its software segment. However, declining gross margins and rising operational costs could impact future profitability.

Simulations Plus SLP recently announced that the FDA (United States Food and Drug Administration) has renewed its DILIsym software licenses for the seventh year in a row. DILIsym is a modernized ...

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and ...

Simulations Plus ( (SLP)) has released its Q1 earnings. Here is a breakdown of the information Simulations Plus presented to its investors. Simulations Plus, Inc., a prominent entity in the biopharma ...

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced ...

Simulations Plus is benefiting from the growing use of computational tools in drug discovery, which would be boosted by the FDA Modernization Act 2.0. The biosimulation market is highly fragmented and ...

Simulations Plus reported Q1 revenue down 3% to $18.4M with a notable mix shift as software revenue fell 17% (48% of revenue) while services rose 16% to 52%; adjusted EBITDA was $3.5M and adjusted EPS ...